The main difference lies in how they work: Wegovy contains semaglutide and works via GLP-1, while Mounjaro contains tirzepatide and combines GIP and GLP-1
Important red flags that require immediate medical attention include: Severe, persistent abdominal pain (possibly radiating to the back) with or without vomiting, which may suggest acute pancreatitis Right upper quadrant pain, fever, or yellowing of the skin/eyes, which could indicate gallbladder disease Reduced urine output or marked dehydration from persistent gastrointestinal symptoms Sudden changes in vision, particularly in those with diabetic retinopathy Cardiovascular symptoms such as palpitations, chest discomfort, or lightheadedness should prompt immediate medical review
These can be distinguished by their selectivities and differential regulation by immune cells
Renal Protection Recent evidence suggests that GLP-1 RAs exhibit significant nephroprotective effects, extending beyond their cardiovascular benefits
This gives us a baseline to ensure that any weight lost is fat, not vital muscle tissue
But Tom Wadden, a psychology professor at the University of Pennsylvanias Perelman School of Medicine, said he is not concerned that semaglutide could cause similar issues